[This corrects the article DOI: 10.3389/fphar.2022.877118.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189544 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1207356 | DOI Listing |
Publication Analysis
Top Keywords
corrigendum elexacaftor-tezacaftor-ivacaftor
4
elexacaftor-tezacaftor-ivacaftor treatment
4
treatment reduces
4
reduces abdominal
4
abdominal symptoms
4
symptoms cystic
4
cystic fibrosis-early
4
fibrosis-early cf-specific
4
cf-specific cfabd-score
4
cfabd-score [this
4
Similar Publications
Corrigendum to "Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 years with Cystic Fibrosis and at Least one F508dek Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor". J Pediatr. 2024 Jun 28; 274:114176.
J Pediatr
November 2024
Cystic Fibrosis Center, Hospital San Carlo, Potenza, Italy.
Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats.
Front Pharmacol
May 2024
Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
[This corrects the article DOI: 10.3389/fphar.2024.
View Article and Find Full Text PDFCorrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score.
Front Pharmacol
May 2023
CF-Zentrum Westbrandenburg, Campus Potsdam, Klinikum Westbrandenburg, Potsdam, Germany.
[This corrects the article DOI: 10.3389/fphar.2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!